Phillips-Medisize Wins Contract to Manufacture First Electronic-Enabled Combination Drug Delivery Product
22.10.2019 18:30:00 EEST | Business Wire | Press release
Phillips-Medisize, a Molex company, announced today an agreement with a leading biotechnology company to manufacture a wearable, electronic-enabled combination product. The product is a post-phase III development-stage combination drug and device that combines two-day, single use, disposable technology for subcutaneous drug delivery.
The wearable combination product – which is replaced every two days – is about the size of a hockey puck, and can either be adhered to the patient’s body, via an adhesive patch, or worn near the infusion site.
Phillips-Medisize, which built devices and supplied key data to support the FDA NDA submission, will provide final assembly, testing and quality control of this electronic combination product. Specifically, Phillips-Medisize will handle the prefilled drug cartridge that fits inside the device. This drug container is aseptically filled and shipped to Phillips-Medisize. Several state-of-the-art Phillips-Medisize facilities are involved in various stages of manufacturing the combination product – including molding, assembly, drug handling, labeling, reconciliation and more.
“This exciting new contract taps over 13 years of Phillips-Medisize’s combination product expertise, which includes cold chain drug handling and first programs with API handling. We have experience in manufacturing both combination and electronic-enabled drug delivery devices, and this is our first product submitted for FDA approval that includes both,” said Matt Jennings, CEO and President, Phillips-Medisize.
Pending receipt of FDA approval, Phillips-Medisize is contracted to provide commercialization services from its Hudson, WI-based manufacturing site. The combination product is slated for launch in 2H 2020. Backed by Phillips-Medisize’s scalability to move to high volume production, the product will be well positioned for a successful market launch.
Strong potential also exists to bring the device onto a connected health platform in the future, by embedding low-cost connectivity that will make it possible to capture and communicate data between patient and provider in order to help monitor adherence.
About Phillips-Medisize
Phillips-Medisize, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, medical device and specialty commercial market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com or www.molex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005826/en/
Contact information
For more information, contact:
Heather Ditzler
Phone +1 715-377-7261
heather.ditzler@phillipsmedisize.com
Paula Kasper (Europe)
Phone +41448383933
paula.kasper@phillipsmedisize.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress12.5.2026 16:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June 11 - 14, 2026, in Stockholm, Sweden. “The breadth of the data that will be showcased at the 2026 EHA Congress highlights the continued advancement of our Hematology and Oncology pipeline and our focus on delivering differentiated medicines for patients with cancer and hematologic diseases,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “These presentations include findings from the frontMIND study, which support the U.S. and EU regulatory applications for tafasitamab (Monjuvi®/Minjuvi®) in patients with first-line diffuse large B-cell lymphoma (DLBCL). Additionally, data presentations for INCA033989, which support our Phase 3 trials, demonstrate the steady advancement of this molecularly targeted therapy that has the potential to revolutionize
Lenovo Enables One-Week Deployment of Production-Ready Agentic AI to Transform Enterprise Workflows12.5.2026 16:00:00 EEST | Press release
Lenovo is enabling enterprises to deploy production-ready, agentic AI solutions in as little as one week1, eliminating the long development cycles that typically delay AI from reaching production, while maintaining enterprise-grade security, governance, and control. This is not theoretical, independent analysis from Signal65 confirms these results in real-world deployments. Lenovo’s Knowledge Super Agent reduced time spent on knowledge-related tasks by 30%, saving up to 120 hours per employee annually. In multiple deployments, organizations reached production up to 24× faster than with custom-built approaches, demonstrating how faster, secure deployment translates directly into faster business outcomes. These results reflect faster deployment and more efficient AI utilization, where each interaction delivers measurable business value. Delivered through the Lenovo AI Library as part of Lenovo Hybrid AI Advantage™, this approach allows organizations to move directly from pilot to operati
Nikkiso Signs Agreement With Maran Tankers Management to Provide Aftermarket Service Support12.5.2026 16:00:00 EEST | Press release
Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) has announced today that it has signed a long-term service agreement with oil tanker shipping firm Maran Tankers Management Inc. Under the five-year agreement, Nikkiso CE&IG will deliver comprehensive global aftermarket support for Maran Tankers’ high pressure pumps, including scheduled cold end valve repairs at defined intervals. To guarantee minimal turnaround time, Nikkiso CE&IG will maintain critical inventory across its Marine Hubs worldwide, enabling cold ends to be received by vessels within days rather than the industry’s average of months. Nikkiso CE&IG will also provide technical guidance to Maran Tankers and carry out extended overhauls during scheduled dry-docking periods. Sean Fanniff, President of Nikkiso CE&IG’s Cryogenic Services Business Unit, said: “With Marine Hubs across Southeast Asia, Europe, the Middle East, the US, and China, we can provide our clients with a coordinated global approach and seamless p
Introducing Cognite Flows™: The First Fully Integrated, AI-Native Industrial Experience that Accelerates Customer Value12.5.2026 16:00:00 EEST | Press release
Cognite, the global leader in Industrial AI, today announced Cognite Flows™, a new standard for industrial experiences that fundamentally redefines how teams engage with AI, apps, and data to address operational challenges. Designed to optimize the daily workflows of frontline teams, Cognite Flows puts everything they need—AI-driven insights and real-time data from multiple apps across every corner of the company—into an easily customized, single-screen workspace. For the first time in an industrial setting, software will adapt to the user, rather than the user needing to adapt to the software. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512315975/en/ Introducing Cognite Flows™: The First Fully Integrated, AI-Native Industrial Experience that Accelerates Customer Value Cognite Flows is the action layer of the Cognite platform, empowering teams to build, scale, and use production-ready workflows 100x faster through adap
Mixpanel Introduces Mixpanel AI, Delivering Always-On Product Intelligence12.5.2026 16:00:00 EEST | Press release
Mixpanel, a global leader in product intelligence and analytics, today introduced Mixpanel AI — the always-on product intelligence system that helps teams ship faster and smarter by understanding how people use their products and what to do next. Unlike query-based analytics assistants, Mixpanel AI monitors your product continuously and surfaces insights and issues before teams think to ask, combining specialized AI agents, a business-aware Context Engine, and native integrations with the tools teams already use. Built on 17 years of product analytics infrastructure and trusted by more than 29,000 customers, Mixpanel AI turns product data into proactive, explainable intelligence that teams can act on — with the business context to make every answer relevant and the verified data foundation to make every answer trustworthy. “At Mixpanel we’re building autonomous product intelligence — always on to match the continuous pace of shipping today, and intelligent because it understands the co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom